Literature DB >> 28274743

Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer.

Emily R York1, Marileila Varella-Garcia1, Tami J Bang2, Dara L Aisner3, D Ross Camidge4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28274743     DOI： 10.1016/j.jtho.2017.02.020

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  19 in total

1.  Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC "capitulate"?

Authors:  Brian Ko; Balazs Halmos
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 2.  Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.

Authors:  D Westover; J Zugazagoitia; B C Cho; C M Lovly; L Paz-Ares
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

Review 3.  Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.

Authors:  Manan P Shah; Joel W Neal
Journal:  Drugs       Date:  2022-04-12       Impact factor: 9.546

Review 4.  New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer.

Authors:  Nicolas Girard
Journal:  Curr Treat Options Oncol       Date:  2022-10-15

Review 5.  Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.

Authors:  Alissa J Cooper; Lecia V Sequist; Jessica J Lin
Journal:  Nat Rev Clin Oncol       Date:  2022-05-09       Impact factor: 65.011

6.  Blocking both epidermal growth factor receptor and mesenchymal-to-epithelial transition pathways in EGFR-mutated lung cancer.

Authors:  Nagio Takigawa; Nobuaki Ochi; Hiromichi Yamane
Journal:  Transl Lung Cancer Res       Date:  2018-12

7.  Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report.

Authors:  Tomoki Tamura; Keita Kawakado; Go Makimoto; Masamoto Nakanishi; Shoichi Kuyama
Journal:  Thorac Cancer       Date:  2021-05-04       Impact factor: 3.500

8.  Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C.

Authors:  Kiyotaka Yoh; Tomonori Hirashima; Hideo Saka; Takayasu Kurata; Yuichiro Ohe; Toyoaki Hida; Anders Mellemgaard; Remy B Verheijen; Xiaoling Ou; Ghada F Ahmed; Manabu Hayama; Ko Sugibayashi; Geoffrey R Oxnard
Journal:  Target Oncol       Date:  2021-05-03       Impact factor: 4.864

9.  PUMA mediates the anti-cancer effect of osimertinib in colon cancer cells.

Authors:  Lingchuan Guo; Shan Huang; Xinwei Wang
Journal:  Onco Targets Ther       Date:  2017-11-03       Impact factor: 4.147

Review 10.  Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy.

Authors:  Tatsuya Nagano; Motoko Tachihara; Yoshihiro Nishimura
Journal:  Cells       Date:  2018-11-15       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.